Testing empagliflozin after a stroke with unknown cause
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had an ischemic stroke or transient ischemic attack (mini-stroke) with no clear cause found after testing.
- You do not have certain heart conditions like atrial fibrillation, a recent heart attack, or a weak heart pump.
- You do not have diabetes or heart failure that already requires a similar drug.
- You have been referred for an implantable loop recorder (a small device under your skin) to check for hidden irregular heartbeats.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving empagliflozin (a diabetes drug also used for heart failure) before, during, or after an emergency angioplasty for a first heart attack can improve recovery. It is for South Asian patients who are having a first heart attack.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests whether giving canagliflozin, a diabetes medication, during clot removal for stroke can improve recovery. It may help protect the brain after a stroke.
Hear when a new Embolic Stroke of Undetermined Source trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.